Tesamorelin Peptide (Egrifta): Dosing, Administration, and What the FDA Label Says

What is tesamorelin, and how does it work?

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). It is sold under the brand name Egrifta, and the current FDA-approved formulation is EGRIFTA WR.

It is not growth hormone. That distinction matters clinically. Injected growth hormone replaces the hormone directly. Tesamorelin acts a step upstream — it signals the pituitary to release the body's own growth hormone, rather than supplying growth hormone directly.

Growth hormone in turn raises IGF-1, and that is where both the intended effect and most of the safety monitoring come from.

What is visceral fat — and is it the fat I can pinch?

This is the single most important thing to understand before considering tesamorelin, and it is where most online material misleads.

Subcutaneous fat sits just under the skin. It is the fat you can pinch between your fingers — on the abdomen, the flanks, the back of the arms.

Visceral fat sits deeper, inside the abdominal cavity, packed around the liver, pancreas, and intestines. You cannot pinch it. Abdominal appearance or firmness alone cannot reliably identify how much visceral fat someone has. It is also the fat most strongly associated with insulin resistance, inflammation, and cardiovascular risk.

Tesamorelin was developed and approved specifically to reduce visceral adipose tissue.

If what bothers you is the fat you can pinch, tesamorelin is not the medication that addresses it, and no honest reading of the trial data suggests otherwise.

Does tesamorelin actually reduce visceral fat?

In the two pivotal trials in adults with HIV-associated lipodystrophy, yes — by a measurable but moderate amount.

At week 26, the mean treatment difference in visceral adipose tissue versus placebo was −31 cm² in Study 1 and −21 cm² in Study 2. Mean trunk fat fell by 1.0 kg and 0.8 kg respectively. Lean body mass rose by 1.3 kg and 1.2 kg.

Those are the actual labeled figures. They describe a real effect on a specific fat compartment — not a transformation.

Is tesamorelin a weight-loss medication?

No, and the label says so outright. Under Limitations of Use, the prescribing information states that the drug "is not indicated for weight loss management as it has a weight neutral effect."

Read the trial numbers again and you can see why: visceral fat went down, lean body mass went up, and overall body weight was essentially unchanged. The composition of the abdomen changed. The number on the scale did not.

If your goal is to weigh less, tesamorelin is not the medication the evidence supports. We would rather tell you that here than after you have paid for it.

How is tesamorelin different from semaglutide or tirzepatide?

They are not competing options for the same goal — they do different things.

Semaglutide and tirzepatide are GLP-1 and GLP-1/GIP receptor agonists. They act primarily on appetite and satiety, and they produce meaningful reductions in total body weight, including both subcutaneous and visceral fat.

Tesamorelin acts on growth-hormone release. It reduces visceral fat specifically and is weight-neutral, with a small increase in lean mass. Learn about medically supervised weight loss programs.

Put simply: if the goal is total weight loss, the GLP-1 class is the evidence-backed choice. Tesamorelin's approved role is narrower — reducing a specific deep abdominal fat compartment in a specific patient population.

Whether the two have any role together is an individualized question for consultation, not something to decide from a website.

Is tesamorelin FDA-approved?

Yes — as a prescription drug, for one indication: "the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy."

Three formulations have been approved over time, and they carry three different daily doses. This is the most common source of dosing confusion online:

Any use outside the approved indication is off-label, and should be identified as such and evaluated individually by a licensed clinician.

How much does tesamorelin reduce fat, and how long does it take?

The registration trials measured their primary endpoint at 26 weeks. That is the timeframe at which the primary labeled effect was measured; individual results and timing vary.

At 26 weeks: visceral adipose tissue down 21–31 cm² versus placebo, trunk fat down 0.8–1.0 kg, lean body mass up 1.2–1.3 kg, body weight essentially unchanged.

Do the results last after treatment stops?

No. This is one of the clearest findings in the label and one of the least discussed online.

Patients who completed the 26-week main phase were re-randomized, and those switched to placebo saw visceral adipose tissue increase by approximately 25 cm² and 24 cm² between weeks 26 and 52 — effectively reversing the gain.

Tesamorelin does not remodel visceral fat permanently. The effect persists while treatment continues and regresses when it stops. Anyone considering it should understand that before starting, because it makes this an ongoing therapy decision rather than a course of treatment.

How is tesamorelin administered, and what is the dose?

Subcutaneous injection, once daily. For EGRIFTA WR, the approved dose is 1.28 mg, which is 0.16 mL of the reconstituted solution.

How often — daily or weekly?

Daily. All three approved formulations are dosed once every day. There is no approved weekly dosing schedule for tesamorelin.

This is worth stating plainly because "tesamorelin dosage per week" is one of the most common searches on this drug, and it reflects a real misunderstanding — most likely carried over from weekly-dosed medications like semaglutide. Tesamorelin is not one of them.

Where should tesamorelin be injected?

The label is specific: inject into the abdomen, rotating injection sites to different areas of the abdomen. It continues: "Do not inject into scar tissue, bruises or the navel."

Abdomen only, rotating, avoiding scar tissue, bruising, and the navel itself.

On a question we see constantly: the labeling directs abdominal injection, not the flank or "love handle" area. The drug was studied for its effect on visceral abdominal fat and the administration instructions reflect how it was studied.

Rotation is not a formality. Injection site redness and itching are among the most commonly reported adverse reactions, and reusing the same site makes local reactions more likely.

What time of day should it be taken?

The labeling specifies once daily and does not designate a time of day.

You will find confident claims online that it must be taken at night to match the body's natural growth-hormone pulse. That is an extrapolation from growth-hormone physiology, not a statement in the approved labeling, and it was not tested as a variable in the registration trials.

Choose a practical daily schedule with your prescriber. The label does not establish that morning or evening dosing is superior.

What if I miss an injection?

Ask your prescriber or pharmacist what to do for a missed dose of your specific product. Do not take extra medication or change your dosing schedule without their guidance.

How should tesamorelin be stored?

For EGRIFTA WR, the label directs: store the 11.6 mg vial at room temperature, 20°C to 25°C (68°F to 77°F), in the original box to protect it from light.

Note that storage requirements have differed between formulations, and compounded preparations may differ again. Follow the instructions that came with the specific product dispensed to you.

What are the most common side effects?

The most frequently reported adverse reactions in the labeling are:

• Arthralgia (joint pain)
• Injection site erythema (redness)
• Injection site pruritus (itching)
• Pain in extremity
• Peripheral edema (swelling)
• Myalgia (muscle pain)

Can tesamorelin cause fluid retention, joint pain, or carpal tunnel symptoms?

Yes — and the label explains the mechanism directly:

"Fluid retention may occur during EGRIFTA WR therapy and is thought to be related to the induction of GH secretion. This manifests as increased tissue turgor and musculoskeletal discomfort resulting in adverse reactions (e.g. edema, arthralgia, and carpal tunnel syndrome)."

These are recognized, mechanism-based effects of raising growth hormone, not idiosyncratic reactions. Swelling, joint discomfort, and hand numbness or tingling should be reported to your prescriber rather than pushed through.

Can tesamorelin raise blood sugar?

Yes, and this is one of the more serious considerations.

The labeling reports an increased risk of developing diabetes on tesamorelin relative to placebo, defined as HbA1c reaching 6.5% or above — with an intent-to-treat hazard odds ratio of 3.3 (CI 1.4, 9.6).

That is a meaningful signal, and it is mechanistically expected: growth hormone opposes insulin action. Glucose status needs to be assessed before starting and monitored during treatment. For anyone with diabetes, prediabetes, or metabolic syndrome, this materially changes the risk-benefit calculation and is a conversation to have with a physician before anything is prescribed.

Does tesamorelin raise IGF-1, and what lab work is required?

Yes, substantially. Among patients treated for 26 weeks, 47% had IGF-1 levels greater than 2 standard deviation scores above normal, and 36% exceeded 3 SDS.

IGF-1 is therefore a monitored parameter, not an optional one. Learn about comprehensive hormone lab testing. Reasonable pre-treatment and on-treatment evaluation includes IGF-1, glucose and HbA1c, and age-appropriate malignancy screening — because of the contraindication below.

Who should not use tesamorelin?

Tesamorelin is contraindicated in:

• Disruption of the hypothalamic-pituitary axis — from pituitary tumor or surgery, head irradiation, or head trauma
• Active malignancy — because tesamorelin raises IGF-1
• Pregnancy
• Known hypersensitivity to tesamorelin or any of its excipients

A history of cancer, as distinct from active malignancy, requires individual evaluation rather than a blanket answer.

Can women use tesamorelin?

The registration trials enrolled both men and women with HIV-associated lipodystrophy, and the approved daily dose does not differ by sex.

Tesamorelin is contraindicated in pregnancy. The label's stated reasoning is direct: modifying visceral adipose tissue offers no benefit to a pregnant woman and could result in fetal harm. Any woman who could become pregnant should have that discussed before starting, not after.

What is the difference between EGRIFTA WR and compounded tesamorelin?

EGRIFTA WR is the FDA-approved drug. It has been through the approval process, is manufactured under the controls that apply to an approved injectable, and carries the labeling quoted throughout this page.

Compounded tesamorelin is prepared by a compounding pharmacy. Compounded preparations are not FDA-approved, are not evaluated for safety or efficacy by the FDA, and may differ in concentration, excipients, and storage requirements from the approved product.

That is a real regulatory distinction, and it is worth understanding which one you are being offered.

What about tesamorelin sold online?

Search for tesamorelin and you will find 10 mg and 20 mg vials, multi-week "cycles," and blends with ipamorelin or CJC-1295 — typically labeled "for research use only."

Vial strength is not the same thing as a daily dose, and research-use products are not FDA-approved tesamorelin medicines. The approved doses are the three above: 2 mg, 1.4 mg, or 1.28 mg once daily depending on formulation.

This is not a matter of opinion. On August 24, 2026, the FDA issued warning letters to multiple peptide sellers, including two Florida companies, over products naming tesamorelin:

• Peptide Partners LLC (Sarasota, FL) — cited over products including "Tesa Peptide (Tesamorelin)" as unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act. Read the letter
• Royal Peptides LLC (Boynton Beach, FL) — cited over tesamorelin products including a blend marketed as combining "Tesamorelin (10mg) and Ipamorelin (3mg)." Read the letter

The FDA addressed the "research use only" disclaimer directly in both letters:

"Despite statements on your product labeling marketing your products 'for research use only' and 'not for human or veterinary use,' evidence obtained from your website establishes that your products are intended to be drugs for human use."

Two practical points follow. A research-use label does not establish that a product meets the safety, quality, sterility, or potency standards of an FDA-approved injectable. And the contraindications above are real: active malignancy, disrupted pituitary function, pregnancy. Deciding on your own whether those apply to you, without labs and without an exam, is the actual risk in self-sourcing.

We do not publish off-label protocols and we will not provide a cycle to run at home.

How do you get tesamorelin?

Tesamorelin is a prescription medication. Obtain it through a licensed pharmacy using a valid prescription; an online listing alone does not establish authenticity or FDA approval.

Obtaining it appropriately means an evaluation: history and examination, laboratory work including IGF-1 and glucose, screening against the contraindications above, and an honest assessment of whether the approved indication — or a defensible off-label rationale — actually applies to you. If it does not, the answer is no. That is a legitimate outcome of a consultation. Explore telehealth care across Florida.

How Much Does Tesamorelin Therapy Cost?

Pricing depends heavily on which product is being compared and what the quoted price includes. Brand-name EGRIFTA WR exists in a very different price category from cash-pay clinic programs. A 2026 public pricing review reported a wholesale acquisition cost benchmark of about $72,000 per year, or roughly $6,000 per month. Public pharmacy cash listings for a 28-day EGRIFTA WR kit have recently been around $10,000–$11,000+. Wholesale acquisition cost is a benchmark before rebates or discounts, and insured patients may pay substantially less depending on coverage and manufacturer assistance.

For comparison, Better Med Spa publicly lists tesamorelin starting at $400. Its separate tesamorelin + ipamorelin combination program is advertised starting at $500. Published clinic prices do not always include the same services, formulation, dose, laboratory work, consultation structure, or follow-up care, so advertised monthly prices are not necessarily equivalent.

For context on the brand product, see the official EGRIFTA WR patient information. EGRIFTA WR is FDA-approved specifically to reduce excess abdominal fat in adults with HIV and lipodystrophy and is not indicated for general weight-loss management.

Pricing benchmarks checked September 2026. Pharmacy cash prices, insurance coverage and outside-provider pricing can change. These are selected public benchmarks rather than a comprehensive market comparison.

What treatment looks like at NovaGenix

Tesamorelin is not something we hand over on request. If it comes up in consultation, this is the process:

1. Evaluation and lab work. History, examination, and baseline labs — including IGF-1, glucose and HbA1c, and hormone panel. Body composition is assessed rather than assumed, because visceral fat and subcutaneous fat are not the same finding and do not have the same answer.

2. A physician decision, including the decision not to treat. Dr. Mackey reviews whether the approved indication applies, whether an off-label rationale is defensible, and whether any contraindication is present. Sometimes the answer is that a different therapy fits better, or that none is warranted. That is a real outcome here.

3. Prescription through legitimate pharmacy channels. If treatment proceeds, medication is dispensed through a licensed pharmacy — not sold from a website under a "research use only" label.

4. Ongoing monitoring. IGF-1 and glucose are rechecked on an interval, because both are known to move on this therapy. Treatment continues only while it is working and remains appropriate.

NovaGenix — Jupiter, Florida Physician-led hormone and metabolic care, serving Palm Beach County and telehealth patients across Florida. Request a consultation →THE PATIENT AND ANY OTHER PERSON RESPONSIBLE FOR PAYMENT HAS A RIGHT TO REFUSE TO PAY, CANCEL PAYMENT, OR BE REIMBURSED FOR PAYMENT FOR ANY OTHER SERVICE, EXAMINATION, OR TREATMENT THAT IS PERFORMED AS A RESULT OF AND WITHIN 72 HOURS OF RESPONDING TO THE ADVERTISEMENT FOR THE FREE, DISCOUNTED FEE, OR REDUCED FEE SERVICE, EXAMINATION, OR TREATMENT.

How does tesamorelin compare to sermorelin?

Both are GHRH analogs, and they are frequently presented as interchangeable. They are not. Tesamorelin holds a current FDA approval with a labeled adult dose. Sermorelin's approval was withdrawn in June 2009 and never covered adults at all, so what is prescribed today is compounded.

The full side-by-side comparison, covering dosing, safety, fat-loss evidence, and whether they can be combined, is here: tesamorelin vs. sermorelin. You can also read our sermorelin dosage and FDA status page.

Ipamorelin is the other comparison patients ask about, and it is a different question entirely — ipamorelin acts on the ghrelin receptor rather than the GHRH receptor, and has never held an FDA approval for any indication. That comparison, including whether the two are combined, is here: tesamorelin vs. ipamorelin.

The comparison patients raise most often is with injected growth hormone itself, which is a different mechanism rather than a different dose. That one — GHRH signalling versus direct replacement, what happens to IGF-1, and what the evidence actually supports — is covered here: tesamorelin vs. HGH.

Related care and reading

Medically supervised weight loss programs · Testosterone evaluation and treatment · Comprehensive hormone lab testing · Telehealth care across Florida

How peptide therapy is evaluated clinically · Sermorelin · Ipamorelin · BPC-157

Prescribing information

Read the FDA-approved EGRIFTA WR prescribing information and Instructions for Use. The pivotal trial results cited above were obtained with the original tesamorelin formulation in adults with HIV-associated lipodystrophy. EGRIFTA formulations have different doses and are not interchangeable.

Educational information does not replace individualized care. Follow the instructions for the medication dispensed to you.